At ESMO, PFS and tolerability data will be shared from the PACIFIC-R global observational study of patients with unresectable, Stage III NSCLC treated with Imfinzi after chemoradiation therapy. Real-world data will provide new compelling evidence for the efficacy and safety profiles of Imfinzi and Tagrisso in NSCLC.
Dato conference trial#
In another late-breaking presentation at ESMO, the COAST Phase II trial will highlight progression-free survival (PFS) results for novel Imfinzi combinations with potential new medicines including oleclumab, an anti-CD73 monoclonal antibody, and monalizumab, an anti-NKG2A monoclonal antibody, in unresectable, Stage III NSCLC, building on the PACIFIC Phase III trial results that established Imfinzi as the standard of care in this setting.ĭata at ESMO will showcase research into combatting resistant disease, including interim results from the ORCHARD Phase II trial studying the combination of Tagrisso (osimertinib) and savolitinib, an oral, potent and highly selective MET tyrosine kinase inhibitor, in patients with advanced EGFR-mutated (EGFRm) NSCLC with MET alterations whose disease progressed on 1st-line Tagrisso. Imfinzi is the only PD-1/PD-L1 immunotherapy to demonstrate both a significant survival benefit and improved response rate in combination with a choice of chemotherapies in ES-SCLC. Leading in lung cancer with established standards of care and novel combinationĪ Presidential Symposium will present results from the final analysis of the POSEIDON Phase III trial at WCLC showing a significant, clinically meaningful survival benefit for the combination of Imfinzi (durvalumab), tremelimumab and chemotherapy in metastatic non-small cell lung cancer (NSCLC).Ī late-breaking presentation at ESMO will feature three-year overall survival (OS) data from the CASPIAN Phase III trial of Imfinzi in extensive-stage small cell lung cancer (ES-SCLC), the longest reported to date for a Phase III trial of chemotherapy and PD-1/PD-L1 immunotherapy in this disease setting. Also, new data on Lynparza will answer critical questions about retreatment with a PARP inhibitor in resistant disease.” Additionally, the data from COAST will support our aim to extend the benefit of Imfinzi in unresectable, Stage III non-small cell lung cancer by combining it with potential first-in-class immunotherapies. Susan Galbraith, Executive Vice President, Oncology R&D said: “The DESTINY-Breast03 data at ESMO will demonstrate the potential for Enhertu to transform the treatment of HER2-positive metastatic breast cancer with a safety profile that supports the potential for Enhertu in early-stage disease.
Our data will also showcase the real-world impact of these medicines in clinical practice.” Our data at WCLC and ESMO illustrate our commitment to building on the benefits of these medicines with novel combinations to extend them to more patients.
A total of 20 oral presentations including one Presidential Symposium will be featured at ESMO between 16 and 21 September.ĭave Fredrickson, Executive Vice President, Oncology Business Unit, said: “ Imfinzi and Tagrisso have redefined outcomes for patients with lung cancer, becoming the established standards of care around the world in certain settings.
There will be five oral presentations including one Presidential Symposium at WCLC, hosted by the IASLC between 8 and 14 September.
0 kommentar(er)
